sodium–glucose cotransporter
The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study
... concentration of the analyte in plasma; CV [%]: Coefficient of variance; CVD: Cardiovascular disease; ECG: Electrocardiogram; HEK293 cells: Human embryonic kidney cells; hERG: Human ether-a-go-go related gene; HPLC-MS/ ...
11
Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus
... Selective sodium glucose cotransporter-2 (SGLT2) inhibitors were extensively studied in type 2 DM and found to have sustained urinary glucose loss, improvement of glycemic control, in addition ...
7
Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
... the sodium-glucose cotransporter 2 (SGLT2) induces glycosuria, reduces glucose toxicity and improves insulin sensitivity and β-cell ...
13
<p>Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide</p>
... Abstract: This comprehensive review covers the historical background, physiology, applica- tion in type 2 diabetes, novel uses, cardiovascular bene fi ts, side effects and contraindications of sodium-glucose ...
12
SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2), A NEW APPROACH IN TYPE 2 DIABETES MELLITUS TREATMENT
... glucose reabsorption in the kidneys and some neurotransmitter dysfunction, are also involved in the pathophysiology of T2DM. [1] The currently available antidiabetic agents have been developed to target one or ...
11
Effect of sodium glucose cotransporter 2 inhibitors on cardiac function and cardiovascular outcome: a systematic review
... [1–3]. Sodium glucose cotransporter 2 (SGLT2) inhibitors have newly emerged as an anti-hyperglycemic drug for type 2 dia- betes mellitus (T2DM) by inhibiting glucose and sodium re- ...
6
Mechanism Underlying Increase of the Serum Magnesium Concentration Observed Following Treatment with Sodium Glucose Cotransporter 2 Inhibitors
... the sodium-glucose cotransporter 2 inhibitor (SGLT2-i) suppressed cardiovascular (CV) events in patients with type 2 diabetes; we recently suggested that increase of the serum magnesium (Mg) by ...
8
The Efficacy of Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors for the treatment of chronic diabetic macular oedema in vitrectomised eyes: a retrospective study
... between our findings and those of the previous studies could not be made, it is possible that the CRT in our cases reduced due to the initiation of SGLT2 inhibitor. More- over, although significant reduction of CRT was ...
6
Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin
... Abstract: One of the most feared repercussions of type 2 diabetes mellitus is the risk of adverse cardiovascular outcomes. The current antidiabetic agents on the market have had difficulty in showing cardiovascular ...
9
Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale
... of glucose-lowering agents in the treatment of ...and sodium-glucose cotransporter 2 (SGLT2) inhibitors, and considers the possible role of such therapy in the management of ...of ...
15
Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
... of Sodium-Glucose Cotransporter-2 Inhibitors (CVD-REAL), which compared SGLT2 inhibitors with other classes of glucose-lowering ...mechanisms, sodium glucose cotransporter ...
16
In-Vitro Antioxidant Activity and Free Radical Scavenging Potential of Phlorizin Derived Sodium Glucose Cotransporter 2 Inhibitor
... modification for the assessment of extent of inhibition of lipid peroxidation using egg yolk homogenate as lipid rich media. 500 μl of 10% egg yolk homogenate was added to tubes containing 100 μl of drug solution of ...
8
Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet
... between the time points. Accordingly, for clarity, only the day 30 data are presented (Table 4). Both empagliflozin and sibutramine had significantly reduced plasma insulin by day 30 when administered alone (P,0.05 and ...
11
Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II–dependent kidney damage
... between sodium intake and blood pressure (BP) [1]. Renal proximal tubular sodium reabsorption is regulated by sodium transporters, including sodium glucose cotransporters (SGLTs), ...
9
Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes
... significant reduction in HbA 1c at 12 weeks compared with baseline of 0.79%, 0.76%, 0.70%, 0.92%, and 0.95% for canagliflozin 50, 100, 200, and 300 mg once daily and 300 mg twice daily, respectively, versus 0.22% for ...
15
Metabolic response to sodium glucose cotransporter 2 inhibition in type 2 diabetic patients
... oral glucose (or, presumably, gastric emptying) but results in a compensatory increase in endogenous glucose release and lower tissue glucose uptake as a consequence of lower glucose and ...
11
The Role of the Kidney and Sodium-Glucose Cotransporter-2 Inhibition in Diabetes Management
... As discussed below, results from clinical trials have confirmed that SGLT2 inhibition improves glycemic control, reduces body weight, and is effective when used as monotherapy or as add-on therapy to commonly used ...
5
SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice
... Sodium glucose cotransporter 2 inhibitors (SGLT2i) represent the most recently approved class of oral medi- cations for the treatment of T2D. Early modeling data predicted that, unlike other classes ...
14
SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives
... and sodium–glucose cotransporter 2 ...versus sodium–glucose cotransporter 2 inhibitors related to A1c reduction, weight loss, cost-effectiveness, cardiovascular outcomes, and ...
11
Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials
... the sodium-glucose cotransporter 2 (SGLT2) inhibi- tors, some glucagon-like peptide-1 receptor agonists (GLP-1RAs) have also demonstrated a marked risk reduction in major adverse CV events (MACE) in ...
6